Thinking Outside The Box On Rx Pricing: From Vaccines To Part D Bundling
Former FDA Deputy Commissioner Sharfstein suggests Vaccine-For-Children model for high value drug purchasing programs during Johns Hopkins drug pricing conference. Bundled payments in Part D is another option put on the table. Medicare head Cavanaugh explains why that option is much harder to accomplish.
You may also be interested in...
Despite headlines about soaring drug costs, Medicare Part D beneficiaries are not seeing much if any increase in their out-of-pocket spending. But that doesn’t necessarily mean that costs of the program are stable – which could open up a new area for policy activity in 2017 and beyond.
“Project Indy” offers a joint manufacturer/payor perspective on how to enable value based pricing. It also sounds like a potential proposal to CMS to volunteer for a pilot project.
The most likely next step in executive branch action on drug pricing will be testing approaches to value-based pricing in categories where pharmaceutical companies are willing participants. That appears to be the message from an HHS official speaking at a DC policy event.